The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg.
source https://medicalxpress.com/news/2026-07-fda-simtriyo-adhd-children-adults.html
source https://medicalxpress.com/news/2026-07-fda-simtriyo-adhd-children-adults.html
Comments
Post a Comment